AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05818826
Drug: Hydrocortisone and normal saline solution
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
Trial: NCT05634473
Drug: Methacholine Chloride
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agonists
Trial: NCT04781816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT06712680
Drug: Test Product HYP-6589
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYP-6589 should be administered orally at the recommended dosage
Trial: NCT05731271
Drug: TST003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV humanized anti-GREM1 monoclonal antibody
Trial: NCT05412992
Drug: DMTS Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMTS applied before surgery and worn for 96 hours
Trial: NCT05412992
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Trial: NCT05780879
Drug: FLAG or CLAG Protocol
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
Trial: NCT06487299
Drug: 0.9% NaCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same volume and color as Iron sucrose.
Trial: NCT04638751
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibitor
Trial: NCT04638751
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any form of chemotherapy
Trial: NCT06462287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo:1 oral capsule time a day for 4 days
Trial: NCT06452771
Drug: Placebo (PB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC injection
Trial: NCT05788601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05914194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NLS-2 matching placebo tablets orally.
Trial: NCT05325203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT06495892
Drug: Diuretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
Trial: NCT05362292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo pill
Trial: NCT04792190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 1 blinded capsule of placebo drug dosed once daily
Trial: NCT06337981
Drug: (AJU-S56 5% and placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
Trial: NCT06337981
Drug: AJU-S56 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (AJU-S56 5%), 1drop/1times, 6times in a day
Trial: NCT06337981
Drug: Placebo(Vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(Vehicle), 1drop/1times, 6times in a day
Trial: NCT05292001
Drug: Iron-Dextran Complex Injection [InFed]
RxNorm normalized name: iron-dextran complex Injection [InFed]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 1000mg dose
Trial: NCT05962255
Drug: Continous intravenous infusion of 5% Glucose solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
Trial: NCT04848402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT03814135
Drug: Hipnos 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, oral, once a day.
Trial: NCT03814135
Drug: Hipnos 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, oral, once a day.
Trial: NCT06717464
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)
Trial: NCT06114719
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
Trial: NCT05393245
Drug: Long-acting muscarinic antagonists (LAMAs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting muscarinic antagonists (LAMAs)
Trial: NCT05393245
Drug: Long-acting β2-agonists (LABAs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-agonists (LABAs)
Trial: NCT05373212
Drug: Euglycemic clamp with BC Combo THDB0207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
Trial: NCT05373212
Drug: Euglycemic clamp with Humalog® Mix25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
Trial: NCT04753489
Drug: Xarelto® film-coated tablet 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
Trial: NCT04418895
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
Trial: NCT04418895
Drug: CAPOX
RxNorm normalized name: Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
Trial: NCT05200312
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Trial: NCT05200312
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Trial: NCT04924621
Drug: Sufentani(T group)
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.02-0.05ug/kg, intravenous injection
Trial: NCT04924621
Drug: Drug use target(T group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Make BIS \< 60 .
Trial: NCT04924621
Drug: Sufentanil(C group)
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 5ug, intravenous injection
Trial: NCT04924621
Drug: Drug use target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Make the BIS between 70 and 80.
Trial: NCT05073939
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo orally
Trial: NCT06003777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as oral suspensions as escalating single doses to be determined.
Trial: NCT05229809
Drug: Yiqi Wenyang Jiedu prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Trial: NCT05229809
Drug: Simulation agent of Yiqi Wenyang Jiedu prescription
RxNorm normalized name: Combinations of antineoplastic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Trial: NCT05701553
Drug: Anti-PD-1/PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection at indicated dose for at least 6 months
Trial: NCT05701553
Drug: S-Adenosyl-Methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally at indicated dose for at least 6 months
Trial: NCT00893854
Drug: Diclophenac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05195203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose(s) of placebo
Trial: NCT05881707
Drug: CKD-828, D064, D702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04883255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of orally-administered placebo
Trial: NCT05922930
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06011265
Drug: Myrbetriq 25Mg Extended-Release Tablet
RxNorm normalized name: Myrbetriq 25mg Extended-Release Tablet (Once-Daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
Trial: NCT06011265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take empty capsule orally
Trial: NCT06006871
Drug: Usual treatment for ADHD
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
Trial: NCT05095298
Drug: Vaccine, COVID19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
Trial: NCT05304442
Drug: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of IV Iron
Trial: NCT05304442
Drug: Ferrous Sulfate 65 mg elemental iron (325 mg tablets)
RxNorm normalized name: ferrous sulfate
DrugBank: Ferrous succinate (DB14489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily by mouth for 42 days
Trial: NCT06049147
Drug: MBF-015 4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBF-015 oral capsules Histone deacetylase inhibitor
Trial: NCT06049147
Drug: MBF-015 16 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBF-015 oral capsules Histone deacetylase inhibitor
Trial: NCT06049147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules filled with cellulose microcrystalline
Trial: NCT05689879
Drug: STOP arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha antagonists withdrawal
Trial: NCT05857566
Drug: RDX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
Trial: NCT05221008
Drug: SHR6508；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A:SHR6508 low dose
Trial: NCT05221008
Drug: SHR6508；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B:SHR6508 medium dose
Trial: NCT05221008
Drug: SHR6508；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C:SHR6508 high dose
Trial: NCT05221008
Drug: SHR6508；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D:SHR6508 high dose(single dose)
Trial: NCT05160363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
Trial: NCT05866692
Drug: TY-2699a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results
Trial: NCT00389753
Drug: Application of Aruba Aloë formula F-BC-096 or control
RxNorm normalized name: BC Original Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06302465
Drug: narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
Trial: NCT06302465
Drug: doxorubicin、cisplatin、methotrexate、ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
Trial: NCT04992468
Drug: Ovulation triggering with GnRH-a+rhCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
Trial: NCT06393803
Drug: 2mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Trial: NCT06393803
Drug: 5mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Trial: NCT06393803
Drug: 10mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Trial: NCT06393803
Drug: 20mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Trial: NCT06393803
Drug: 30mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Trial: NCT06393803
Drug: 40mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Trial: NCT06393803
Drug: 50mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Trial: NCT06393803
Drug: 60mg KH607 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Trial: NCT06307847
Drug: SP5M001 inj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-filled syringe
Trial: NCT06307847
Drug: Synovian inj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-filled syringe
Trial: NCT05501639
Drug: long-acting β2-agonists (LABA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-acting β2-agonists (LABA)
Trial: NCT05501639
Drug: inhaled corticosteroids (ICS)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled corticosteroids (ICS)
Trial: NCT05269459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
Trial: NCT04861779
Drug: HSK29116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HSK29116
Trial: NCT04794738
Drug: SHR8554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8554 Injection; high dose
Trial: NCT04794738
Drug: SHR8554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8554 Injection; low dose
Trial: NCT04907253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT02065323
Drug: Standard ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
Trial: NCT05290662
Drug: oNKord®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Trial: NCT05290662
Drug: Cyclophosphamide/Fludarabine (Cy/Flu)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting conditioning regimen
Trial: NCT06178367
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
Trial: NCT06289946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will apply placebo moisturizing cream to the wrist
Trial: NCT05296317
Drug: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14
Trial: NCT05296317
Drug: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14
Trial: NCT04877678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical looking placebo, twice a day
Trial: NCT04601116
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet per day for 2 years
Trial: NCT05573698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered by intravenous (IV) injection
Trial: NCT05007548
Drug: Ga68-Dolacga Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
Trial: NCT05698394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
Trial: NCT06704100
Drug: Fosamprenavir Calcium & Sodium Alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID
Trial: NCT06719310
Drug: ACC017+FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC017+FTC/TAF
Trial: NCT06719310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06716918
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who have received antenatal corticosteroids (betamethasone or dexamethasone) prior to cesarean section as part of their prenatal care.
Trial: NCT06715839
Drug: [68Ga]Ga-DOTA-H2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.
Trial: NCT06715839
Drug: [18F]F-RESCA-RB14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.
Trial: NCT06715839
Drug: [68Ga]Ga-NOTA-T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.